Skip to content

JDRF Applauds Congress for Passage of $300 Million for Type 1 Diabetes Research

December 16, 2010

JDRF Applauds Congress for Passage of $300 Million for Type 1 Diabetes Research and Thanks Supporters for Advocacy Efforts for Special Diabetes Program Renewal – A Statement from JDRF President and CEO, Jeffrey Brewer:  NEW YORK, Dec. 9, 2010

“Today Congress passed a multi-year renewal of the Special Diabetes Program (SDP), ensuring that studies on promising diabetes treatments and avenues toward a cure continue uninterrupted. As the father of a son living with type 1 diabetes, and as CEO of JDRF, one of the leading advocates for the renewal of this program, I applaud the U.S. government for its continued commitment to end this disease.

At a time when the incidence of diabetes, both type 1 and 2, is rising and when a CDC modeling study predicts that one in three Americans will be living with diabetes by the year 2050, our nation cannot afford to falter in its support for research that will help to lessen and ultimately eliminate the burden of diabetes from our healthcare system.

We have made progress toward better treatments. We have also made progress toward a cure.  But we’re not there yet. Advancing science takes time, and breakthroughs are unpredictable. We at JDRF are trying to accelerate the process by identifying and filling gaps to help bring products to patients as quickly and safely as possible by providing significant funding and direction to type 1 diabetes research. But we can’t do it alone. And this is why we are excited to see the U.S. government renew its commitment to diabetes research today. The combination of federal diabetes research funding and private investments through JDRF has created one of the most effective public-private partnerships focused on disease research.

The SDP is unique because it supplements annually-appropriated NIH-research funding with a mandatory funding stream for type 1 diabetes research. Currently, the SDP represents 35 percent of all the federal research on type 1 diabetes. Since its establishment in 1997, the program has produced tangible scientific and clinical results, and real returns on the federal investment in type 1 diabetes research.

An example of an advance, funded both by the SDP and JDRF, was announced earlier this year when results from a clinical trial conducted by The National Eye Institute of the National Institutes of Health (NIH) and the Diabetic Retinopathy Clinical Research Network (DRCR.net) showed that a drug (known as Lucentis), when combined with the current standard treatment of laser therapy, is more effective than the current medical treatment in treating diabetic eye disease for people with type 1 and type 2 diabetes. The pivotal data showed that after one year, nearly half of the patients in the trial treated with drug and laser therapy improved their vision by at least two lines on a standard eye chart, concluding that the drug when combined with the current standard treatment of laser therapy, improved vision significantly. This is really good news for those with diabetes and for the productivity of our workforce as whole – diabetic eye disease is the most common cause of visual loss in working age Americans.

Also, both the SDP and JDRF have provided significant support for the development an artificial pancreas – a closed-loop system that will enable a person with diabetes to maintain normal glucose levels by providing the right amount of insulin at the right time, just as the pancreas does in individuals without diabetes. Tests have been conducted successfully in a hospital environment. The next step is for these devices to be tested in outpatient settings.

Congress’ action today marks the fifth time the SDP has been renewed, committing $150 million in annual funding for two years for the program. Its renewal will allow us to continue and build on the program’s advances in its initial years by translating those discoveries into treatments and eventually cures for people with diabetes.

Thanks to the strong, ongoing bipartisan support of Congress, the SDP is making a real difference. We also thank the Members of Congress who have championed this program and recognize the importance of accelerating research efforts our effort to find a cure for type 1 diabetes. And, thanks to our volunteers who have shared their stories about the toll that diabetes has on their families, and encouraged their Members of Congress to take action.

Together we can help to improve the lives of those living with type 1 diabetes and eventually eliminate the disease once and for all.”

Please call your Senators and Representatives and thank them for their strong support of the Special Diabetes Program. We have provided the contact information for your Senators and a few talking points below, to locate your Representative’s contact information, please CLICK HERE.

Sen. Kay Bailey Hutchison – (202) 224-5922
Sen. John Cornyn III – (202) 224-2934

When you call the office, ask to speak with the health aide. Use the below points to guide your conversation:

  • I am a constituent, and I want to thank you for supporting the renewal of the Special Diabetes Program. The program is providing tangible advances in diabetes research, treatment, and prevention efforts, and is bring us closer to a cure for diabetes and its complications.
  • I know first hand the burden of diabetes. [Provide your short personal story].

About JDRF
JDRF is a leader in setting the agenda for diabetes research worldwide, and is the largest charitable funder and advocate of type 1 research. The mission of JDRF is to find a cure for diabetes and its complications through the support of research. Type 1 diabetes is a disease which strikes children and adults suddenly and requires multiple injections of insulin daily or a continuous infusion of insulin through a pump. Insulin, however, is not a cure for diabetes, nor does it prevent its eventual and devastating complications which may include kidney failure, blindness, heart disease, stroke, and amputation.

Since its founding in 1970 by parents of children with type 1 diabetes, JDRF has awarded more than $1.4 billion to diabetes research, including more than $100 million last year.

.

To learn more about the JDRF Dallas chapter, visit our JDRF Dallas website!

Advertisements
No comments yet

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: